AUTHOR CORRECTION
Volume 54, no. 5, p. 1340–1351, 2016, https://doi.org/10.1128/JCM.00198-16.
Page 1349, column 1: The last three paragraphs preceding the Acknowledgments section should be replaced with the following.
Description of Mycobacterium virginiense sp. nov.
Mycobacterium virginiense (vir.gi.ni.en′se. N.L. neut. adj. virginiense, of or belonging to the state of Virginia, USA, where the type strain was originally isolated).
Cells are typically acid-fast, slowly growing, and nonpigmented on Middlebrook 7H10 agar. The isolates grew in >7 days. They did not grow at 42°C, and their optimal growth temperature was 35°C. By the Clinical and Laboratory Standards Institute (CLSI) guidelines, the isolates were susceptible to clarithromycin, ethambutol, rifabutin, and trimethoprim-sulfamethoxazole (TMP-SMX) and resistant to rifampin, amikacin, the quinolones, including moxifloxacin and ciprofloxacin, and the tetracycline analogues doxycycline and minocycline (48).
The proposed type strain MO-233T produced tenosynovitis in a 58-year-old woman from Virginia (case 1 in the paper by Ridderhof et al. [3]). The isolate was negative for the following biochemical properties: niacin, 3- and 14-day arylsulfatase, urease, and tellurite reduction. The isolate was positive (5+) for nitrate, semiquantitative catalase >45 mm, and Tween hydrolysis (3). The complete 16S rRNA gene, the hsp65 gene sequence of the Telenti fragment, and regions III and V of the rpoB gene are closely related to but unique from other members of the M. terrae complex.
The type strain is MO-233T (= DSM 100883T = CIP110918T).